BiotechTube
Fuse Vectors

Fuse Vectors

Copenhagen, Denmark· Est.
fusevectors.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

Fuse Vectors is an innovative private biotech tackling a critical bottleneck in the gene therapy field: the inefficient production of viral vectors. Its core technology is a fully scalable, cell-free enzymatic system that manufactures AAVs with high purity, consistency, and a very high percentage of fully packaged ('filled') capsids. By replacing outdated cell-based methods, Fuse aims to enable faster, cheaper, and more reliable development of gene therapies, positioning itself as a potential platform technology provider to the broader industry. The company is in a pre-revenue, pre-clinical platform development stage, building its team and advancing its technology towards GMP readiness.

Drug DeliveryRNA & Gene TherapyViral Technology

Technology Platform

A fully scalable, cell-free enzymatic system for manufacturing adeno-associated virus (AAV) vectors. The platform aims to produce AAVs with >99% filled capsids, high purity, and consistency in a single step, replacing traditional cell-based production methods.

Funding History

1
Total raised:$3.5M
Seed$3.5M

Opportunities

The massive and growing gene therapy market is severely constrained by costly, slow, and inconsistent AAV manufacturing.
Fuse's cell-free platform addresses this core bottleneck, offering a potential paradigm shift towards faster, cheaper, and higher-quality vector production.
This creates a large addressable market as a platform provider to hundreds of gene therapy developers.

Risk Factors

Key risks include the technical challenge of fully validating that cell-free AAVs perform as well as or better than traditional vectors in vivo, the significant hurdle of scaling the process to GMP standards, and competition from established manufacturers and alternative new technologies.
As a pre-revenue startup, it also faces funding and execution risks.

Competitive Landscape

Fuse competes with established CDMOs using HEK293 and baculovirus/Sf9 cell systems (e.g., Catalent, Lonza, Thermo Fisher) and other innovators working on next-gen AAV production (e.g., using stable producer cell lines or other novel platforms). Its differentiation hinges on the claimed step-change in quality (>99% full capsids) and simplicity of its cell-free system.

More companies in Cell & Gene Therapy →More companies in Denmark →